Winton Group LTD Galectin Therapeutics Inc Transaction History

Winton Group LTD

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$2.79 - $4.32 $84,246 - $130,446	-30,196 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$3.0 - $4.05 $30,249 - $40,836	-10,083 Reduced 25.03%	30,196 $111,000
Q2 2019 Jul 08, 2019	BUY	$3.61 - $5.0 $39,659 - $54,930	10,986 Added 37.5%	40,279 $167,000
Q1 2019 May 13, 2019	BUY	$3.86 - $6.02 $113,070 - $176,343	29,293 New	29,293 $150,000

9.69M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.